MondegarAI
Velan Capital Investment Management LP

Q3 2024 · 13F-HR

Velan Capital Investment Management LPholdings as filed

Filed 2024-11-14 · accession 0001848809-24-000011

$106.9M
Reported value
18
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
471871202JSPRJASPER THERAPEUTICS INC$27.0M25.2%1,433,828CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$20.2M18.9%350,666CommonSOLE
78464A870XBISPDR SER TR$14.8M13.9%150,000CALLSOLE
427746102HRTXHERON THERAPEUTICS INC$13.9M13.0%6,986,744CommonSOLE
89157D105TRMLTOURMALINE BIO INC$8.5M7.96%331,190CommonSOLE
76200L309RZLTREZOLUTE INC$3.9M3.63%800,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$3.0M2.81%300,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$2.5M2.36%1,290,323CommonSOLE
45779A846NSPRINSPIREMD INC$2.4M2.27%904,029CommonSOLE
810648105SCPHSCPHARMACEUTICALS INC$2.4M2.21%517,668CommonSOLE
872381108TELATELA BIO INC$1.9M1.77%747,410CommonSOLE
68404V100OPTINOSE INC$1.4M1.34%2,146,608CommonSOLE
488445206ZVRAZEVRA THERAPEUTICS INC$1.4M1.30%200,000CommonSOLE
74365U107TARAPROTARA THERAPEUTICS INC$1.1M0.98%574,000CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$1.0M0.96%50,000CommonSOLE
83086J200SKYESKYE BIOSCIENCE INC$825,2880.77%211,071CommonSOLE
49721T507KPRXKIORA PHARMACEUTICALS INC$447,3360.42%122,223CommonSOLE
88032L605TENXTENAX THERAPEUTICS INC$288,3320.27%83,333CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.